LEADER 03824nam 2200649 450 001 9910787716603321 005 20230124191238.0 010 $a0-309-28477-5 010 $a0-309-28475-9 035 $a(CKB)2670000000517632 035 $a(EBL)3564291 035 $a(SSID)ssj0001137137 035 $a(PQKBManifestationID)11659533 035 $a(PQKBTitleCode)TC0001137137 035 $a(PQKBWorkID)11118928 035 $a(PQKB)11136775 035 $a(MiAaPQ)EBC3564291 035 $a(Au-PeEL)EBL3564291 035 $a(CaPaEBR)ebr10863849 035 $a(OCoLC)929505334 035 $a(EXLCZ)992670000000517632 100 $a20140320h20132013 uy| 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 14$aThe CTSA program at NIH $eopportunities for advancing clinical and translational research /$fCommittee To Review the Clinical and Translational Science Awards Program at the National Center for Advancing Translational Sciences, Board on Health Sciences Policy ; Alan I Leshner, Sharon F. Terry, Andrea M. Schultz and Catharyn T. Liverman, editors ; Institute of Medicine of the National Academies 210 1$aWashington, District of Columbia :$cNational Academies Press,$d[2013] 210 4$dİ2013 215 $a1 online resource (178 p.) 300 $aDescription based upon print version of record. 311 $a0-309-28474-0 320 $aIncludes bibliographical references. 327 $aIntroduction -- A vision for the CTSA program in a changing landscape -- Leadership -- Crosscutting topics -- Conclusion: opportunities for action. 330 $a"The NIH contracted with the Institute of Medicine (IOM) in 2012 to conduct a study to assess and provide recommendations on appropriateness of the CTSA Program's mission and strategic goals and whether changes were needed. The committee was also tasked with providing an independent appraisal of and advice on the implementation of the program by the National Center for Advancing Translational Sciences (NCATS), while exploring the contributions of CTSAs in accelerating the development of new therapeutics, facilitating disease-specific and child health research, and enhancing the integration of research funded by NIH institutes and centers. To conduct this study, the IOM convened a 13-member committee with expertise in community outreach and engagement, public health and health policy, bioethics, education and training, pharmaceutical research and development, program evaluation, clinical and biomedical research, and child health research, along the full continuum of clinical and translation research. The committee's overarching conclusion is that the CTSA Program is contributing significantly to the advancement of clinical and translational research and is therefore a worthwhile investment that would benefit from a variety of revisions to make it more efficient and effective"--$cSource other than Library of Congress. 606 $aMedicine$xResearch$xGovernment policy$zUnited States 606 $aMedicine$xResearch$zUnited States$xEvaluation 606 $aMedicine$xResearch$zUnited States$xFinance 606 $aResearch$zUnited States 615 0$aMedicine$xResearch$xGovernment policy 615 0$aMedicine$xResearch$xEvaluation. 615 0$aMedicine$xResearch$xFinance. 615 0$aResearch 676 $a610.72 702 $aLeshner$b Alan I.$f1944- 702 $aTerry$b Sharon 702 $aSchultz$b Andrea M. 702 $aLiverman$b Catharyn T. 712 02$aInstitute of Medicine (U.S.).$bBoard on Health Sciences Policy, 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910787716603321 996 $aThe CTSA program at NIH$93695930 997 $aUNINA